Drug enrichment and discovery from schizophrenia genome-wide association results: An analysis and visualisation approach

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Gaspar, H A ^a,b   Breen, G ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; NERVE PROTEIN; NEUROLEPTIC AGENT;

AGONISTS; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; DRUG REPOSITIONING; GENE REGULATORY NETWORK; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROCEDURES; PROTEIN ANALYSIS; SAMPLE SIZE; SCHIZOPHRENIA; SYNAPSE; TRANSPORT AT THE CELLULAR LEVEL;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; DRUG REPOSITIONING; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; PHARMACOGENETICS; PROTEIN INTERACTION MAPPING; SAMPLE SIZE; SCHIZOPHRENIA; SYNAPSES;

EID: 85030329866     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-12325-3     Document Type: Article

References (52)

1. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. Am. J. Hum. Genet. 90, 7-24 (2012).
2. Lichtenstein, P. et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373, 234-239 (2009).
3. Gottesman, I. I. & Shields, J. A polygenic theory of schizophrenia. Proc. Natl. Acad. Sci. USA. 58, 199-205 (1967).
4. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427 (2014).
5. Lencz, T. & Malhotra, A. K. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol. Psychiatry 20, 820-826 (2015).
6. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856-860 (2015).
7. Sanseau, P. et al. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol. 30, 317-320 (2012).
8. Wang, Z.-Y. & Zhang, H.-Y. Rational drug repositioning by medical genetics. Nat. Biotechnol. 31, 1080-1082 (2013).
9. Breen, G. et al. Translating genome-wide association findings into new therapeutics for psychiatry. Nat. Neurosci. 19, 1392-1396 (2016).
10. Ruderfer, D. M. et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry 3, 350-357 (2016).
11. de Jong, S., Vidler, L. R., Mokrab, Y., Collier, D. A. & Breen, G. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. J. Psychopharmacol. 30, 826-830 (2016).
12. Chang, S., Fang, K., Zhang, K. & Wang, J. Network-Based Analysis of Schizophrenia Genome-Wide Association Data to Detect the Joint Functional Association Signals. PLoS One 10, e0133404 (2015).
13. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43, 969-976 (2011).
14. Ripke, S. et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45, 1150-1159 (2013).
15. Bishop, C. M., Svensén, M. & Williams, C. K. I. GTM: The Generative Topographic Mapping. Neural Comput. 10, 215-234 (1998).
16. Olier, I., Vellido, A. & Giraldo, J. Kernel generative topographic mapping. In ESANN 2010, 18th European Symposium on Artificial Neural Networks, Bruges, Belgium, April 28-30, 2010, Proceedings (2010).
17. Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447-52 (2015).
18. Anttila, V. et al. Analysis of shared heritability in common disorders of the brain. bioRxiv 048991. https://doi.org/10.1101/048991 (2016).
19. Hosák, L. & Libiger, J. Antiepileptic drugs in schizophrenia: a review. Eur. Psychiatry 17, 371-378 (2002).
20. Imbrici, P., Camerino, D. C. & Tricarico, D. Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front. Genet. 4, 76 (2013).
21. Berger, S. M. & Bartsch, D. The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function. Cell Tissue Res. 357, 463-476 (2014).
22. Dubovsky, S. L. & Buzan, R. The Role of Calcium Channel Blockers in the Treatment of Psychiatric Disorders. CNS Drugs 4, 47-57 (1995).
23. Dall'Igna, O. P., Tort, A. B. L., Souza, D. O. & Lara, D. R. Cinnarizine has an atypical antipsychotic profile in animal models of psychosis. J. Psychopharmacol. 19, 342-346 (2005).
24. Greenbaum, L., Rigbi, A., Teltsh, O. & Lerer, B. Role of genetic variants in the CHRNA5-CHRNA3-CHRNB4 cluster in nicotine dependence risk: importance of gene-environment interplay. Mol. Psychiatry 14, 828-830 (2009).
25. Chen, J. et al. Genetic Relationship between Schizophrenia and Nicotine Dependence. Sci. Rep. 6, 25671 (2016).
26. Won, H. et al. Chromosome conformation elucidates regulatory relationships in developing human brain. Nature. https://doi. org/10.1038/nature19847 (2016).
27. Evins, A. E. et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 311, 145-154 (2014).
28. Buchanan, R. W. et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 165, 82-89 (2008).
29. Fatemi, S. H., Folsom, T. D. & Thuras, P. D. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr. Res. 128, 37-43 (2011).
30. Chaki, S. Anxiolytic- and Antidepressant-Like Profile of ATC0065 and ATC0175: Nonpeptidic and Orally Active Melanin- Concentrating Hormone Receptor 1 Antagonists. J. Pharmacol. Exp. Ther. 313, 831-839 (2004).
31. Taldone, T., Zito, S. W. & Talele, T. T. Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg. Med. Chem. Lett. 18, 479-484 (2008).
32. Teff, K. L. et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 62, 3232-3240 (2013).
33. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219 (2015).
34. Maciejewski, H. Competitive and self-contained gene set analysis methods applied for class prediction. in Computer Science and Information Systems (FedCSIS), 2011 Federated Conference on 55-61 (2011).
35. 1000 Genomes Project Consortium. et al. A global reference for human genetic variation. Nature 526, 68-74 (2015).
36. Yates, A. et al. Ensembl 2016. Nucleic Acids Res. 44, D710-6 (2016).
37. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289-300 (1995).
38. Benjamini, Y. & Yekutieli, D. The Control of the False Discovery Rate in Multiple Testing under Dependency. Ann. Stat. 29, 1165-1188 (2001).
39. Gaspar, H. A., Baskin, I. I., Marcou, G., Horvath, D. & Varnek, A. GTM-Based QSAR Models and Their Applicability Domains. Mol. Inform. 34, 348-356 (2015).
40. Pebesma, E. J. Multivariable geostatistics in S: the gstat package. Comput. Geosci. 30, 683-691 (2004).
41. Csardi, G. & Nepusz, T. The igraph software package for complex network research. InterJournal, Complex Systems 1-9, 2006 (1695).
42. Varin, T., Schuffenhauer, A., Ertl, P. & Renner, S. Mining for bioactive scaffolds with scaffold networks: improved compound set enrichment from primary screening data. J. Chem. Inf. Model. 51, 1528-1538 (2011).
43. Wilcoxon, F. Individual Comparisons by Ranking Methods. In Breakthroughs in Statistics (eds Kotz, S. & Johnson, N. L.) 196-202 (Springer New York, 1992).
44. Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29-36 (1982).
45. Brendan Bulik-Sullivan, H. F. LD Score Regression (LDSC). (Broad Institute of MIT and Harvard / MIT Department of Mathematics, 2015).
46. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291-295 (2015).
47. Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9 (2017).
48. Wagner, A. H. et al. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 44, D1036-44 (2016).
49. Roth, B. L., Lopez, E., Patel, S. & Kroeze, W. K. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? Neuroscientist 6, 252-262 (2000).
50. Gray, K. A., Yates, B., Seal, R. L., Wright, M. W. & Bruford, E. A. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 43, D1079-85 (2015).
51. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
52. Koscielny, G. et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 45, D985-D994 (2017).